1. Minimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapies
- Author
-
Lord, Phillip, Aguillon, Juan C, Anderson, Amy E, Appel, Silke, Benitez-Ribas, Daniel, Ten Brinke, Anja, Broere, Femke, Cools, Nathalie, Cuturi, Maria Cristina, Diboll, Julie, Geissler, Edward K, Giannoukakis, Nick, Gregori, Silvia, van Ham, S Marieke, Lattimer, Staci, Marshall, Lindsay, Harry, Rachel A, Hutchinson, James A, Isaacs, John D, Joosten, Irma, van Kooten, Cees, Lopez Diaz de Cerio, Ascension, Nikolic, Tatjana, Oral, Haluk Barbaros, Sofronic-Milosavljevic, Ljiljana, Ritter, Thomas, Riquelme, Paloma, Thomson, Angus W, Trucco, Massimo, Vives-Pi, Marta, Martinez-Caceres, Eva M, Hilkens, Catharien M U, LS Immunologie, dI&I RA-I&I I&I, School of Computing Science [Newcastle], Newcastle University [Newcastle], Institute of Cellular Medicine [Newcastle], Instituto de Ciencias Biomédicas [Santiago, Chile] (Facultad de Medicina), Broegelmann Research Laboratory [Bergen, Norway] (Department of Clinical Science), University of Bergen (UiB), Department of Immunology [Barcelona, Spain], Hospital Clinic i Provincial de Barcelona (SCReN)-Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas [Barcelona, Spain] (CIBERehd), Department of Immunopathology [Amsterdam, The Netherlands], University of Amsterdam [Amsterdam] (UvA), Department of Infectious Diseases and Immunology [Utrecht, The Netherlands], Utrecht University [Utrecht]-WHO Collaborating Center for Campylobacter /OIE Reference Laboratory for Campylobacteriosis (Utrecht), Laboratory of Experimental Hematology [Wilrijk, Belgium] (Faculty of Medicine and Health Sciences), University of Antwerp (UA)-Vaccine & Infectious Disease Institute [Wilrijk, Belgium] (VAXINFECTIO), Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Institut de transplantation urologie-néphrologie (ITUN), Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes), Department of Surgery, Section of Experimental Surgery [Regensburg, Germany], University Hospital Regensburg, Institute of Cellular Therapeutics [Pittsburgh, PA, USA], Allegheny Health Network, Division of Regenerative Medicine, Stem Cells and Gene Therapy [Milan, Italy], IRCCS Ospedale San Raffaele [Milan, Italy]-S. Raffaele Scientific Institute-San Raffaele Telethon Institute for Gene Therapy [Milan, Italy] (SR-Tiget), Department of Laboratory Medicine [Nijmegen, the Netherlands], Radboud Proteomics Centre [Nijmegen, the Netherlands], Department of Nephrology [Leiden, The Netherlands], Leiden University Medical Center (LUMC), Area of Cell Therapy [Pamplona, Spain], University Clinic of Navarra - CUN [Pamplona, Spain], Department of Immunohematology and Blood Transfusion [Leiden, The Netherlands], Department of Immunology [Bursa, Turkey] (Faculty of Medicine), Uludağ Üniversitesi = Uludag University, Institute for the Application of Nuclear Energy [Belgrade, Serbia] (INEP), University of Belgrade [Belgrade], Regenerative Medicine Institute [Galway, Ireland], National University of Ireland [Galway] (NUI Galway), Thomas E. Starzl Transplantation Institute [Pittsburgh, PA, USA], University of Pittsburgh School of Medicine, Pennsylvania Commonwealth System of Higher Education (PCSHE)-Pennsylvania Commonwealth System of Higher Education (PCSHE), Immunology Division [Badalona, Spain], Health Sciences Research Institute [Badalona, Spain]-Germans Trias i Pujol University Hospital [Badalona, Spain], CIBER of Diabetes and Associated Metabolic Diseases [Madrid, Spain] (CIBERDEM), Instituto de Salud Carlos III [Madrid] (ISC), Department of Cellular Biology, Physiology and Immunology [Barcelona, Spain], Autonomous University of Barcelona, A grant from the European Cooperation in Science and Technology (COST) for the AFACTT project (Action to Focus and Accelerate Cell-based Tolerance-inducing Therapies, BM1305). COST is part of the EU Framework Programme Horizon 2020., ~, LS Immunologie, dI&I RA-I&I I&I, Uludağ Üniversitesi/Tıp Fakültesi/İmmünoloji Anabilim Dalı., Oral, Haluk Barbaros, K-7285-2012, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas [Barcelona, Spain] (CIBERehd)-Hospital Clinic i Provincial de Barcelona (SCReN), San Raffaele Telethon Institute for Gene Therapy [Milan, Italy] (SR-Tiget)-IRCCS Ospedale San Raffaele [Milan, Italy]-S. Raffaele Scientific Institute, Germans Trias i Pujol University Hospital [Badalona, Spain]-Health Sciences Research Institute [Badalona, Spain], Germans Trias i Pujol University Hospital [Badalona, Barcelona, Spain] (GTPUH)-Health Sciences Research Institute [Badalona, Spain], Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Universitat Autònoma de Barcelona (UAB), and Le Bihan, Sylvie
- Subjects
0301 basic medicine ,Science & technology - other topics ,Macrophage ,610 Medizin ,lcsh:Medicine ,Celltherapy ,Dendritic cells ,Computational Science ,Cell therapy ,0302 clinical medicine ,Autoimmune disease ,Prevalence ,Tolerogenicdendriticcells ,Medicine ,Disease ,Antigen-presentingcells ,Regulatorymacrophages ,ddc:610 ,[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology ,Antigen presenting cell ,General Neuroscience ,Tolerogenic dendritic cells ,Gold standard ,General Medicine ,3. Good health ,Program sustainability ,General Agricultural and Biological Sciences ,Engineering sciences. Technology ,Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5] ,Dendritic cell ,Human ,Translational Medicine ,Minimuminformationmodel ,Immunology ,Antigen-presenting cells ,Computational biology ,Multidisciplinary sciences ,Article ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,Clinical Trials ,Immune response ,Minimum information model ,Antigen-presenting cell ,Transplantation ,business.industry ,lcsh:R ,Translational medicine ,Reporting guidelines ,Regulatory macrophages ,030104 developmental biology ,business ,Tolerogenic antigen resenting cell ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology ,Dendritic Cells ,Mixed Lymphocyte Culture Test ,Regulatory T Lymphocyte ,Model ,030215 immunology - Abstract
Cellular therapies, with tolerogenic antigen-presenting cells (tolAPC) show great promise for the treatment of autoimmune diseases and for the prevention of destructive immune responses after transplantation The methodologies for generating tolAPC vary greatly between different laboratories, making it difficult to compare data from different studies; thus constituting a major hurdle for the development of standardised tolAPC therapeutic products. Here we describe an initiative by members of the tolAPC field to generate a minimum information model for tolAPC (MITAP), providing a reporting framework that will make differences and similarities between tolAPC products transparent. In this way, MITAP constitutes a first but important step towards the production of standardised and reproducible tolAPC for clinical application. This work was supported by a grant from the European Cooperation in Science and Technology (COST) for the AFACTT project (Action to Focus and Accelerate Cell-based Tolerance-inducing Therapies; BM1305). COST is part of the EU Framework Programme Horizon 2020. peer-reviewed
- Published
- 2016